UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 148

Sortiert nach

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

The lancet oncology, 2015-04, Vol.16 (4), p.395-405

2015

Volltextzugriff (PDF)

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer

Breast cancer research and treatment, 2022-11, Vol.196 (1), p.153-162

2022

Volltextzugriff (PDF)

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Clinical cancer research, 2007-04, Vol.13 (8), p.2329-2334

2007

Volltextzugriff (PDF)

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages

Oncology (Williston Park, N.Y.), 2017-03, Vol.31 (3), p.198-208

2017

Volltextzugriff (PDF)

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2400-2407

2021

Volltextzugriff (PDF)

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3232-3239

2011

Volltextzugriff (PDF)

The Proteasome as a Target for Cancer Therapy

Clinical cancer research, 2003-12, Vol.9 (17), p.6316-6325

2003

Volltextzugriff (PDF)

CYP2C83 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

Breast cancer research and treatment, 2012-07, Vol.134 (1), p.401-410

2012

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5305-5313

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1800-1805

2009

Volltextzugriff (PDF)

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2460-2467

2016

Volltextzugriff (PDF)

The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life

Psycho-oncology (Chichester, England), 2008-09, Vol.17 (9), p.948-953

2008

Volltextzugriff (PDF)

Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

Clinical breast cancer, 2018-02, Vol.18 (1), p.29-37

2018

Volltextzugriff (PDF)

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2502-2512

2005

Volltextzugriff (PDF)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Frontiers in oncology, 2022-02, Vol.11, p.810023-810023

2022

Volltextzugriff (PDF)

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

NPJ breast cancer, 2022-09, Vol.8 (1), p.103-103, Article 103

2022

Volltextzugriff (PDF)

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

Breast cancer research and treatment, 2020-06, Vol.181 (3), p.623-633

2020

Volltextzugriff (PDF)

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

Current drug metabolism, 2012-09, Vol.13 (7), p.911

2012

Volltextzugriff (PDF)

American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome

JNCI : Journal of the National Cancer Institute, 2005-08, Vol.97 (15), p.1137-1142

2005

Volltextzugriff (PDF)

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Cancer chemotherapy and pharmacology, 2007-10, Vol.60 (5), p.759-766

2007

Volltextzugriff (PDF)

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.945-954

2011

Volltextzugriff (PDF)

A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.8172-8183

2023

Volltextzugriff (PDF)

635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A726-A726

2023

Volltextzugriff (PDF)

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

Cancer chemotherapy and pharmacology, 2014-07, Vol.74 (1), p.117-123

2014

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(147)
Bücher
(1)

Sprache

Englisch
(148)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(90)
Science & Technology
(90)
Humans
(88)
Female
(80)
Oncology
(75)
Middle Aged
(67)
Adult
(63)
Aged
(59)
Biological And Medical Sciences
(37)
Medical Sciences
(36)
Tumors
(36)
Breast Neoplasms - Drug Therapy
(35)
Male
(35)
Breast Cancer
(32)
Treatment Outcome
(30)
Chemotherapy
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Breast Neoplasms - Pathology
(27)
Antineoplastic Agents
(24)
Antineoplastic Agents - Therapeutic Use
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

The Proteasome as a Target for Cancer Therapy

CYP2C83 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life

Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

Suchergebnisse filtern